Prostate Cancer News Archive

Dementia Not Linked to ADT for Prostate Cancer

Dementia Not Linked to ADT for Prostate Cancer

In a study, androgen deprivation therapy did not increase risks for vascular or any other form of dementia among men with prostate cancer who underwent definitive radiation therapy.

Bladder Cancer Risk Higher With Radiation Therapy for Prostate Cancer

Bladder Cancer Risk Higher With Radiation Therapy for Prostate Cancer

In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.

Simple Clinical Factors May Aid Prognosis in nmCRPC

Simple Clinical Factors May Aid Prognosis in nmCRPC

A combination of age, comorbidity, and PSA doubling time can risk stratify cause of death among men with non-metastatic castration-resistant prostate cancer, study suggests.

Cancer Risk Varies for Hispanics, Including in Puerto Rico

Cancer Risk Varies for Hispanics, Including in Puerto Rico

Men in Puerto Rico have higher prostate cancer incidence rates than other Hispanics, non-Hispanic whites.

Bladder Cancer Risk Not Lowered With Androgen Deprivation

Bladder Cancer Risk Not Lowered With Androgen Deprivation

In a study, men with prostate cancer who received androgen deprivation therapy did not have a lower subsequent risk of developing bladder cancer.

Cryoablation a Possible Alternative Prostate Cancer Treatment

Cryoablation a Possible Alternative Prostate Cancer Treatment

Medium-term oncologic results are comparable to those of radical prostatectomy and radiation therapy, according to investigators.

Study: Private Payer Coverage of Prostate MRI Lagging

Study: Private Payer Coverage of Prostate MRI Lagging

Only 11% of private insurers in the United States cover prostate MRI in biopsy-naïve patients with suspect prostate cancer.

Surgery + Radiation for Advanced PCa Offers Better Survival

Surgery + Radiation for Advanced PCa Offers Better Survival

Radical prostatectomy plus adjuvant radiotherapy is associated with better cancer-specific and overall survival than radiotherapy plus androgen deprivation therapy in patients with locally or regionally advanced prostate cancer.

High Cholesterol Ups Risk of Aggressive Prostate Cancer

High Cholesterol Ups Risk of Aggressive Prostate Cancer

Men in the highest vs lowest tertile of total cholesterol had a 42% increased risk of Gleason 8-10 prostate cancer, Finnish study finds.

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

Some prostate cancer cells lack androgen receptor, and they proliferate faster than those that express androgen receptor under androgen-deficient conditions.

Annual PSA Screening Best for Reducing Prostate Cancer Deaths

Annual PSA Screening Best for Reducing Prostate Cancer Deaths

A study of 400,887 men in an integrated health system, the first to evaluate various PSA screening intervals and age groups, concluded that yearly screening is the interval of choice.

Apalutamide Preserves HRQoL in Nonmetastatic CRPC

Apalutamide Preserves HRQoL in Nonmetastatic CRPC

New analysis of the SPARTAN trial shows that apalutamide maintains health-related quality of life while lowering the risk of metastasis.

Prostate Cancer Radiotherapy Effective Long-Term

Prostate Cancer Radiotherapy Effective Long-Term

Australian study shows 8-year overall survival and biochemical relapse-free rates of 78.4% and 68.1%, respectively.

Prostate Cancer ADT Linked to Higher Risk of Liver Diseases

Prostate Cancer ADT Linked to Higher Risk of Liver Diseases

Men who received androgen deprivation therapy for prostate cancer were 54% more likely to be diagnosed with non-alcoholic fatty liver disease than those who did not, a study found.

Prostate Cancer AS Loss to Follow-Up Risk at 2 Years Estimated at 10%

Prostate Cancer AS Loss to Follow-Up Risk at 2 Years Estimated at 10%

The risk being lost to follow-up while on active surveillance for prostate cancer is higher among blacks than whites, according to a study.

Prazosin May Lower Prostate Cancer Recurrence Risk After Radiotherapy

Prazosin May Lower Prostate Cancer Recurrence Risk After Radiotherapy

LUTS treatment with the alpha-blocker prazosin was associated with significantly lower 2- and 5-year biochemical recurrence rates vs tamsulosin and non-use of alpha-blockers.

LDR Brachytherapy Beneficial In High-Risk Prostate Cancer

LDR Brachytherapy Beneficial In High-Risk Prostate Cancer

Low-dose-rate brachytherapy is associated with excellent long-term biochemical control and survival, new study finds.

Prostate Cancer Risk Lower In Men in Physically Demanding Jobs

Prostate Cancer Risk Lower In Men in Physically Demanding Jobs

Even low cumulative exposure to physical strain at work is associated with a decreased risk of prostate cancer, study finds.

Prostate MRI Use Ups Odds of Prostate Cancer Observation

Prostate MRI Use Ups Odds of Prostate Cancer Observation

In a study, men with low-risk prostate cancer were nearly 2-fold more likely to be managed with observation if they had a prostate MRI during the diagnostic work-up.

Decline in Surgical Overtreatment of Prostate Cancer Reported

Decline in Surgical Overtreatment of Prostate Cancer Reported

At a major tertiary referral center, the use of radical prostatectomy for insignificant prostate cancer decreased from 15% in 2009 to 3% in 2016, a study found.

Prostate Cancer Diagnoses Increase Men's Suicide Risk

Prostate Cancer Diagnoses Increase Men's Suicide Risk

A patient's risk of suicide is doubled within the first year following a prostate cancer diagnosis, according to a new meta-analysis.

Obese Prostate Cancer Patients Do Worse After Radical Prostatectomy

Obese Prostate Cancer Patients Do Worse After Radical Prostatectomy

Study of Korean radical prostatectomy patients showed that those who were obese had significant increased odds of biochemical recurrence and cancer-specific mortality

Cytoreductive Surgery for Metastatic PCa Linked to More Complications

Cytoreductive Surgery for Metastatic PCa Linked to More Complications

Cytoreductive radical prostatectomy (RP) for metastatic prostate cancer (PCa) is associated with higher complication rates and longer hospital stays than RP for non-metastatic PCa.

Persistent Cancer Screening Gaps Revealed in New CDC Report

Persistent Cancer Screening Gaps Revealed in New CDC Report

From 2000 to 2015 screening for breast, cervical, and prostate cancers decreased significantly, whereas screening for colorectal cancer increased significantly.

Use of Post-RP High Dose Radiotherapy Increasing

Use of Post-RP High Dose Radiotherapy Increasing

Physicians increasingly are prescribing high dose and very high dose radiation therapy after radical prostatectomy despite an absence of randomized trials supporting the practice.

First-Line Enzalutamide May Confer a Survival Benefit for mCRPC

First-Line Enzalutamide May Confer a Survival Benefit for mCRPC

Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

SBRT Appears Effective for Oligometastatic Prostate Cancer

SBRT Appears Effective for Oligometastatic Prostate Cancer

Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.

Prostate Cancer Brachytherapy Outcomes Linked to PSADT

Prostate Cancer Brachytherapy Outcomes Linked to PSADT

Shorter PSA double times are associated with worse disease-specific, metastasis-free, and overall survival, study finds.

Prostate Cancer Outcomes Improve With Tailored Post-RP Treatment

Prostate Cancer Outcomes Improve With Tailored Post-RP Treatment

Radiation therapy dose escalation, pelvic lymph node irradiation, and hormone therapy duration are prescribed based on patient and tumor characteristics.

Prostate Cancer Risk Reduced in Men with Very Low Free Testosterone

Prostate Cancer Risk Reduced in Men with Very Low Free Testosterone

Men in the bottom 10th of free testosterone level vs those with higher levels were found to have a 23% decreased risk of prostate cancer.

Study Supports Prostate Cancer Active Surveillance for Younger Men

Study Supports Prostate Cancer Active Surveillance for Younger Men

Younger men with prostate cancer are less likely to experience Gleason score upgrading and pathologic progression on repeat biopsy.

Salvage RARP Feasible, Effective

Salvage RARP Feasible, Effective

According to researchers, 57.3% of men who underwent salvage robot-assisted radical prostatectomy were pad-free at 12 months.

Shorter ADT Course May Suffice for High-Risk Prostate Cancer

Shorter ADT Course May Suffice for High-Risk Prostate Cancer

New study shows no significant difference in overall survival between 18 and 36 months of androgen deprivation therapy used in combination with radiation therapy.

Aggressive Therapy Warranted for Gleason 10 Prostate Cancer

Aggressive Therapy Warranted for Gleason 10 Prostate Cancer

Regardless of treatment modality, men with Gleason 10 prostate cancer have high 5-year overall survival rates, new study finds.

PET/CT May Improve Imaging of Recurrent Prostate Cancer

PET/CT May Improve Imaging of Recurrent Prostate Cancer

Early study results are encouraging, but high-quality data that validate PET/CT against a reliable reference standard are lacking.

Adding MRI Does Not Boost Prostate Cancer Upgrading Rate

Adding MRI Does Not Boost Prostate Cancer Upgrading Rate

MRI with targeted prostate biopsy plus systematic biopsy fails to improve detection of upgrading in men on active surveillance for prostate cancer vs systematic biopsy alone.

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.

Prostate Cancer ADT Ups Thromboembolic Event Risk

Prostate Cancer ADT Ups Thromboembolic Event Risk

Pulmonary embolism is associated with GnRH agonist use and orchiectomy.

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk PCa

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk PCa

The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.

Advanced Prostate Cancer Variant More Common Than Thought

Advanced Prostate Cancer Variant More Common Than Thought

Incidence of tx-emergent small-cell neuroendocrine prostate cancer 17% among those with mCRPC.

Focal HIFU Effective Over 5 Years for PCa

Focal HIFU Effective Over 5 Years for PCa

Failure-free survival was 88% at 5 years among patients with nonmetastatic prostate cancer who underwent focal therapy with high-intensity focused ultrasound.

Automated Bone Scan Index Prognostic for Prostate Cancer

Automated Bone Scan Index Prognostic for Prostate Cancer

aBSI validated as prognostic biomarker of survival in metastatic castration-resistant prostate cancer

Conservative Management Up for Low-Risk Prostate Cancer in Veterans

Conservative Management Up for Low-Risk Prostate Cancer in Veterans

More conservative management and active surveillance utilized at VA hospitals from 2005 to 2015.

Metformin Added to Prostate Cancer ADT Ups Survival

Metformin Added to Prostate Cancer ADT Ups Survival

Metformin plus androgen deprivation therapy is associated with a lower death risk vs ADT alone in men without diabetes, study of US veterans shows.

Enzalutamide Delays Metastasis in CRPC

Enzalutamide Delays Metastasis in CRPC

Men receiving enzalutamide plus ADT had a significant 71% lower risk for metastasis or death compared with men receiving placebo plus ADT.

Testosterone Levels May Be Determined in Childhood

Testosterone Levels May Be Determined in Childhood

Children who migrated to the UK from Bangladesh before puberty and Bangladeshis born in the UK had significantly higher levels of testosterone compared with life-long residents of Bangladesh.

Prostate Cancer Vaccine Found Not to Improve Survival

Prostate Cancer Vaccine Found Not to Improve Survival

In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.

End-of-Life Prostate Cancer-Related Complications Characterized

End-of-Life Prostate Cancer-Related Complications Characterized

Men with advanced prostate cancer at diagnosis have an elevated risk of spinal cord compression, renal failure, and other cancer-related morbidities.

Prostate Biopsy Complications Deter Patients From Re-Biopsy

Prostate Biopsy Complications Deter Patients From Re-Biopsy

Study participants with acute urinary retention after TRUS-guided prostate biopsy were 4.5 times more likely to skip a recommended re-biopsy than men who had no initial biopsy-related complications.

Long-Term Data Support Finasteride for PCa Prevention

Long-Term Data Support Finasteride for PCa Prevention

Clinicians can rest easier about recommending finasteride to more men, according to experts.

Prostate Cancer Treatment Side Effects Linked to Distress

Prostate Cancer Treatment Side Effects Linked to Distress

Those with worse emotional distress also report worse urinary, sexual, bowel functions.

Biparametric MRI Improves Detection of Significant PCa

Biparametric MRI Improves Detection of Significant PCa

If externally validated, bpMRI could be used to triage men for prostate biopsy.

Abiraterone for mCRPC May Benefit Blacks More Than Whites

Abiraterone for mCRPC May Benefit Blacks More Than Whites

Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.

Robotics Involved in Most Urologic Cancer Surgeries

Robotics Involved in Most Urologic Cancer Surgeries

In 2015, 69% of surgeries for prostate, bladder, and kidney cancer were performed with robotic assistance, a new meta-analysis shows.

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.

AUA Updates Castration-Resistant Prostate Cancer Clinical Guideline

AUA Updates Castration-Resistant Prostate Cancer Clinical Guideline

"We are confident this guideline is fully aligned with the latest science on treatments for patients with non-metastatic and metastatic CRPC," said Michael Cookson, MD, member of the 2018 amendment panel.

PSA Level 3 Months After Radiation Tx May Predict Outcome

PSA Level 3 Months After Radiation Tx May Predict Outcome

Findings for men with intermediate- and high-risk prostate cancer.

Current Smokers at Risk for Worse Prostate Cancer Outcomes

Current Smokers at Risk for Worse Prostate Cancer Outcomes

In a meta-analysis, smokers had an 89% greater risk of dying from prostate cancer compared with nonsmokers.

FDA Approves Yonsa for Metastatic Castration-Resistant Prostate Cancer

FDA Approves Yonsa for Metastatic Castration-Resistant Prostate Cancer

The approval of Yonsa was based on 2 randomized, placebo-controlled, multicenter Phase 3 studies in patients with mCRPC.

From 2008 to 2014, Prostate Cancer Testing, Treatment Down

From 2008 to 2014, Prostate Cancer Testing, Treatment Down

Sharpest decrease seen in privately insured men after 2011.

Laser Focal Ablation of Prostate Cancer Improves Outcomes

Laser Focal Ablation of Prostate Cancer Improves Outcomes

Men with low-risk PCa who underwent partial gland ablation with vascular-targeted photodynamic therapy were less likely than those on AS to require radical treatment.

Node-Positive Prostate Cancer on the Rise

Node-Positive Prostate Cancer on the Rise

The percentage of prostate cancer patients with positive lymph nodes increased from 2.4% in 2010 to 4.7% in 2014.

BPH, Cancers Linked to Peyronie's Disease

BPH, Cancers Linked to Peyronie's Disease

Men with Peyronie's disease have elevated risks of benign prostatic hyperplasia, prostatitis, and testis and prostate cancer, new studies reveal.

Testosterone Therapy Safe Despite Prostate Cancer History

Testosterone Therapy Safe Despite Prostate Cancer History

Findings from the largest study to date examining the effect of TRT in prostate cancer patients build on previous evidence showing that the treatment does not affect disease progression risk.

Incontinence, Impotence Risk After RP Linked to Metabolic Syndrome

Incontinence, Impotence Risk After RP Linked to Metabolic Syndrome

At 1 year post-op, patients with MetS prior to prostate surgery had a significantly lower continence rate than those without MetS (75.4% vs 82.6%).

Clinical Variables Predict Radiographic Progression in mCRPC

Clinical Variables Predict Radiographic Progression in mCRPC

Extent of disease and change in PSA were the strongest predictors of disease progression in men with chemotherapy-naïve mCRPC treated with abiraterone.

Focal vs Total PCa Cryoablation Better for Sexual Function

Focal vs Total PCa Cryoablation Better for Sexual Function

Oncologic outcomes are similar for focal and total cryoablation for localized prostate cancer, but patients report significantly better sexual function after focal cryoablation.

Negative Confirmatory Biopsy Predicts Lower PCa Progression Risk

Negative Confirmatory Biopsy Predicts Lower PCa Progression Risk

Men on active surveillance for prostate cancer who had a negative confirmatory biopsy experienced an 88% decreased risk of progression to treatment.

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

Following laparoscopic radical prostatectomy, men with posterior index tumors had 76% increased risk of biochemical recurrence vs those with anterior prostate tumors.

Gleason Score at Surgical Margin Affects BCR Risk

Gleason Score at Surgical Margin Affects BCR Risk

Gleason score at the margin can better stratify biochemical recurrence-free rates, according to study findings.

AS May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

AS May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

Men with Gleason 6 and Gleason 3+4 prostate cancer who undergo radical prostatectomy after a period on active surveillance have similar surgical outcomes.

Novel Blood Test Improves Detection of High-Grade Prostate Cancer

Novel Blood Test Improves Detection of High-Grade Prostate Cancer

IsoPSA can correctly rule out high-grade prostate cancer 93% of the time and thus has the potential to reduce the number of unnecessary prostate biopsies.

Optimal Post-Radical Prostatectomy Follow-up Schedule Proposed

Optimal Post-Radical Prostatectomy Follow-up Schedule Proposed

Investigators suggest PSA testing frequencies based on post-operative baseline PSA.

Overall, Drinking Wine Does Not Impact Prostate Cancer Risk

Overall, Drinking Wine Does Not Impact Prostate Cancer Risk

Findings show small increased risk with white wine, decreased risk with red wine

Predictors of Adverse Pathology After Prostate Cancer Surgery ID'd

Predictors of Adverse Pathology After Prostate Cancer Surgery ID'd

High PSA levels and larger number of positive biopsy cores are associated with positive surgical margins and extracapsular extension/seminal vesicle invasion after radical prostatectomy.

Smoking Ups Bladder Cancer Risk, Lowers Prostate Cancer Risk

Smoking Ups Bladder Cancer Risk, Lowers Prostate Cancer Risk

Men and women who smoke are at 2.3-fold and 2.7-fold increased risk of bladder cancer compared with non-smokers.

Cancer Incidences and Burden Expected to Shift in HIV-Positive

Cancer Incidences and Burden Expected to Shift in HIV-Positive

Prostate and lung cancer expected to emerge as the most common types by 2030.

USPSTF Updates Prostate Cancer Screening Recommendations

USPSTF Updates Prostate Cancer Screening Recommendations

The new statement emphasizes shared decision-making on screening for men aged 55 to 69 years who are at average risk for prostate cancer.

Surgical Overtreatment of Prostate Cancer May Be Decreasing

Surgical Overtreatment of Prostate Cancer May Be Decreasing

Canadian study shows that nearly all men undergoing radical prostatectomy in Eastern Ontario in recent years have clinically significant prostate cancer.

Gleason 4+3 vs 3+4 PCa Tied To Higher Risk of Metastasis at Diagnosis

Gleason 4+3 vs 3+4 PCa Tied To Higher Risk of Metastasis at Diagnosis

Men with Gleason score (GS) 4+3 prostate cancer have a 3-fold higher risk of distant metastasis at diagnosis than those with GS 3+4 PCa.

Obesity Linked to Lower Death Risk in Non-metastatic CRPC

Obesity Linked to Lower Death Risk in Non-metastatic CRPC

Obese men with non-metastatic castration-resistant prostate cancer have a 21% decreased risk of death compared with normal weight men, according to a study.

Cancer Screening More Likely After a Previous False Positive

Cancer Screening More Likely After a Previous False Positive

Findings for both men and women with a false-positive prostate or breast cancer test result.

BRCA Mutations Up Risk for PCa, Other Cancers

BRCA Mutations Up Risk for PCa, Other Cancers

Increased incidence of malignant disease, specifically prostate, melanoma, pancreas, breast cancers

Survey Highlights Emotional Responses to Prostate Cancer

Survey Highlights Emotional Responses to Prostate Cancer

Sexual dysfunction was a chief complaint among survey respondents with prostate cancer.

Myocarditis Rare Side Effect of Immune Checkpoint Inhibitors

Myocarditis Rare Side Effect of Immune Checkpoint Inhibitors

Myocarditis with ICIs may be more common than initially thought; responds to higher steroid dosages

Diet, Exercise With Behavioral Counseling Can Reduce ADT Side Effects

Diet, Exercise With Behavioral Counseling Can Reduce ADT Side Effects

A novel component of an interventional program was cognitive-behavioral counseling administered in a group setting to promote behavioral change.

Socioeconomics May Not Explain Racial Gap in Prostate Cancer Mortality

Socioeconomics May Not Explain Racial Gap in Prostate Cancer Mortality

In a study, race independently predicted prostate cancer-specific mortality beyond a number of risk factors, including health insurance status.

Low-Dose Abiraterone Noninferior for Castration-Resistant PCa

Low-Dose Abiraterone Noninferior for Castration-Resistant PCa

Low-dose AA with low-fat breakfast had greater effect on PSA; similar effect to standard dose

Adjuvant RT Plus ADT Beneficial in Selected Prostate Cancer Cases

Adjuvant RT Plus ADT Beneficial in Selected Prostate Cancer Cases

Study identifies which PCa patients with positive lymph nodes may have improved survival with the addition of adjuvant radiotherapy to androgen-deprivation therapy.

Biopsy-to-RP Delay May Up Prostate Cancer Recurrence Risk

Biopsy-to-RP Delay May Up Prostate Cancer Recurrence Risk

Researchers concluded that a greater than 90-day interval from prostate biopsy to radical prostatectomy increases the risk of biochemical recurrence among men with Gleason 3+4 disease.

Metastatic Prostate Cancer at Diagnosis in Decline

Metastatic Prostate Cancer at Diagnosis in Decline

Study documents a drop in the incidence of de novo metastatic PCa from 1980 to 2011 in the United States.

Finasteride Cuts Prostate Cancer Risk Long Term

Finasteride Cuts Prostate Cancer Risk Long Term

New study shows that men are at lower risk of prostate cancer for years after they stop taking the medication.

MRI Scans Can Avert Many Prostate Biopsies

MRI Scans Can Avert Many Prostate Biopsies

In a large international trial, pre-biopsy MRI scans spared 28% of men from having to undergo a biopsy and resulted in a lower detection of clinically insignificant cancers vs standard biopsy.

Dose-Escalated RT Does Not Improve Survival in Intermediate-Risk PCa

Dose-Escalated RT Does Not Improve Survival in Intermediate-Risk PCa

Researchers observed reductions in biochemical failure and distant metastasis rates in patients who had dose-escalated radiation therapy.

No Advantages With Aggressive Treatment in Metastatic Prostate Cancer

No Advantages With Aggressive Treatment in Metastatic Prostate Cancer

However, mortality higher with conservative therapy in locally advanced, non-metastatic prostate cancer.

Single PSA Screening Has No Effect on Prostate Cancer Mortality

Single PSA Screening Has No Effect on Prostate Cancer Mortality

Findings from a large study of men in the United Kingdom do not support single PSA testing for population-based screening.

EBRT+BT+ADT May Be Optimal for High-Grade PCa

EBRT+BT+ADT May Be Optimal for High-Grade PCa

In a study, extremely dose-escalated radiotherapy combined with androgen deprivation therapy offered the best cancer-specific survival among men with Gleason 9-10 prostate cancer.

Nocturia May Contribute to Sleep Problems in ADT Recipients

Nocturia May Contribute to Sleep Problems in ADT Recipients

In a 12-month study, men with prostate cancer treated with ADT reported more nocturia episodes than men with prostate cancer treated with prostatectomy alone and men with no history of cancer.

MRI May Help Cut Down on Unnecessary Prostate Biopsies

MRI May Help Cut Down on Unnecessary Prostate Biopsies

Multiparametic MRI findings added to conventional clinical predictors decreases the number of false-positive biopsy results without increasing the number of clinically significant tumors left undiagnosed, study finds.

FDA Oks Drug for Non-metastatic Castration-Resistant Prostate Cancer

FDA Oks Drug for Non-metastatic Castration-Resistant Prostate Cancer

Apalutamide prolonged metastasis-free survival by 2 years compared with placebo.

Sign Up for Free e-newsletters